TickerFacts.

Evofem Biosciences, Inc. (EVFM): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$1.99M
Year ended 2025-12-31
-$472.0K
Trailing 12 months to 2026-06-30
2013-12-31: -$12.90M2014-12-31: -$9.57M2015-12-31: -$37.91M2016-12-31: -$16.25M2017-12-31: -$19.24M2018-12-31: -$56.50M2019-12-31: -$55.10M2020-12-31: -$104.83M2021-12-31: -$146.67M2022-12-31: -$70.41M2023-12-31: -$8.97M2024-12-31: -$3.88M2025-12-31: -$1.99M-$1.99M
2013-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$1.99Mn/m2026-03-11, From 2025-01-01
2024-12-31-$3.88Mn/m2026-03-11, From 2024-01-01
2023-12-31-$8.97Mn/m2025-03-24, From 2023-01-01
2022-12-31-$70.41Mn/m2024-03-27, From 2022-01-01
2021-12-31-$146.67Mn/m2023-04-27, From 2021-01-01
2020-12-31-$104.83Mn/m2022-03-10, From 2020-01-01
2019-12-31-$55.10Mn/m2021-03-04, From 2019-01-01
2018-12-31-$56.50Mn/m2020-03-12, From 2018-01-01
2017-12-31-$19.24Mn/m2019-03-01, From 2017-01-01
2016-12-31-$16.25Mn/m2018-02-26, From 2016-01-01
2015-12-31-$37.91Mn/m2018-02-26, From 2015-01-01
2014-12-31-$9.57Mn/m2017-03-23, From 2014-01-01
2013-12-31-$12.90Mn/a2016-03-29, From 2013-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Evofem Biosciences, Inc. (EVFM)2025-12-31-$1.99Mn/m
Scynexis Inc (SCYX)2025-12-31-$5.28Mn/m
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31-$20.75Mn/m
Sol-Gel Technologies Ltd. (SLGL)2025-12-31$322.0Kn/m
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31-$147.78Mn/m
Alumis Inc. (ALMS)2025-12-31-$369.52Mn/m
uniQure N.V. (QURE)2025-12-31-$177.96Mn/m
Entrada Therapeutics, Inc. (TRDA)2025-12-31-$128.51Mn/m
Celularity Inc (CELU)2025-12-31-$13.25Mn/m

Compare EVFM, SCYX, CASIF, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗